This protocol explains how to measure the effect of genetic variation associated with neurodevelopmental disorders on deubiquitylating enzyme activity by combining recombinant protein purification with ubiquitin chain cleavage assays.
Neurodevelopmental disorders (NDDs) are associated with impairments in nervous system function but often remain poorly understood at the molecular level. Discrete disorders caused by single genes provide models to investigate mechanisms driving atypical neurodevelopment. Variants of genes encoding deubiquitylating enzyme (DUB) family proteins are associated with several NDDs, but there is a need to determine the pathogenic mechanisms of disorders driven by these gene variants. The impact of gene variants on DUB activity can be experimentally determined using a substrate-independent in vitro ubiquitin cleavage assay. This assay does not require knowledge of downstream substrates to directly measure catalytic activity. Here, the protocol for determining the impact of gene variants on enzymatic activity is modeled using the DUB Ubiquitin Specific Protease 27, X-linked (USP27X), which is mutated in X-linked intellectual disability 105 (XLID105). This experimental pipeline can be used to clarify the mechanisms underlying neurodevelopmental disorders driven by variants in DUB genes.
Neurodevelopmental disorders (NDDs) arise from diverse etiologies with environmental or genetic determinants that drive atypical nervous system development1. Next-generation sequencing genetic testing has linked an increasing number of variants in ubiquitin system-related genes with genetic NDDs2. The ubiquitin system catalyzes the ligation of the small protein modifier ubiquitin to primarily lysine residues in protein substrates to drive changes in cellular behavior, including localization, stability, protein-protein interactions, or activity3. Ubiquitylation is mediated by E1 activating, E2 conjugating, and E3 ligase enzymes4 and is reversible by the activity of deubiquitylating enzymes (DUBs) that catalyze the cleavage and removal of ubiquitin from protein substrates5. Ubiquitin can be ligated to the substrate as a monomer (monoubiquitylation) or polymeric chains (polyubiquitylation) that are formed on any of the seven lysine residues (K6, K11, K27, K29, K33, K48, K63) or the M1 residue of ubiquitin. These different ubiquitin chain topologies and their combinations create a cellular code that is key for signal transduction6.
DUBs such as USP27X, USP7, USP9X, USP48, STAMBP, OTUD4, OTUD6B, and OTUD5 have been associated with NDDs2,7,8,9,10,11. For most NDDs, the molecular mechanisms that drive pathogenesis remain experimentally undefined. Some of the DUBs driving recently described disorders are poorly understood and lack known cellular readouts that can be used to assess the impact of genetic variation on protein function. In vitro, ubiquitin chain cleavage assays overcome this limitation as substrate-independent DUB activity readouts that can measure the impact of gene variants on enzymatic activity12.
In vitro ubiquitin cleavage assays have been used since the 1980s. These assays using radiolabeled substrates allowed for the discovery of the first DUBs, including isopeptidase, identified for its capacity to deubiquitylate Histone H2A13, and ubiquitin carboxyl-terminal hydrolase (UCH), identified by its ability to hydrolyze ubiquitin from a variety of chemical conjugates14,15,16. Further, radiolabeled polyubiquitylated full-length proteins or peptides were used to identify isopeptidase T and several UCHs and ubiquitin-specific proteases (UBPs) from erythrocytes and skeletal muscle, respectively17,18,19,20. Ubiquitin chains of a defined length and linkage type (K48-linked tetra-ubiquitin) were first used to measure the DUB activity of Isopeptidase T21. Since then, this assay has become the gold standard to measure DUB activity in mutational analyses22,23. The refinement of this assay currently allows visualization of ubiquitin cleavage via electrophoresis and conventional gel stains such as Coomassie blue, SYPRO orange, ruby, and silver stain or fluorescent or immunoblotting-based detection12,24. Molecular aspects of DUB activity, such as minimum chain length and linkage specificity25,26,27,28, can be clarified by using ubiquitin chains of different lengths (e.g., di-, tri-, tetra-ubiquitin) and linkages (K6, K11, K27, K29, K33, K48, K63, linear) in functional assays. NDD-associated variants can drive DUB activity defects that are ubiquitin chain linkage type specific11.
A di-ubiquitin cleavage assay using purified recombinant DUB proteins can directly measure the impact of NDD variants on DUB activity. USP27X, which is mutated in the NDD X-linked intellectual disability disorder 105 (XLID105)7,28 models the process presented here. This approach allows for the determination of how DUB activity is disrupted by gene variants in existing and unknown DUB-associated NDDs.
The following protocol can be adapted for recombinant proteins using various affinity tags expressed in different strains of competent cells. Depending on the protein being expressed, the culturing and overnight expression conditions may require optimization of the OD600 at expression induction, expression time, expression temperature, and IPTG concentration. An overview of the protocol is illustrated in Figure 1. The details of the reagents and the equipment used in this study are listed in the Table of Materials.
1. Transformation of competent Rosetta 2 E. coli cells with the recombinant GST-USP27X expression plasmid
NOTE: To maintain the sterility of the bacterial culture, perform steps where media containers are open under a Bunsen burner flame. To allow optimal oxygen transfer, perform bacterial culture shaking in a benchtop temperature-controlled shaker with an orbit of 19 mm to 50 mm and a speed of 200 rpm29.
2. Overnight bacterial expression of recombinant protein from expression plasmid
NOTES: To maintain the sterility of the bacterial culture, perform steps where media containers are open under a Bunsen burner flame. To allow optimal oxygen transfer, perform bacterial culture shaking in a benchtop temperature-controlled shaker with an orbit of 19 mm to 50 mm and a speed of 200 rpm29. Measure culture OD600 using a spectrophotometer.
3. Protein purification by gravity-flow affinity column
NOTE: The resin, binding, wash, elution, and storage buffers appropriate for each purification will depend on the recombinant protein being purified. Collect samples from the cell pellet, supernatant, flow-through, wash fractions, and elution fractions in SDS-PAGE buffer. Perform SDS-PAGE and Coomassie staining for the samples to evaluate the success of the purification. Perform purification at 4 °C and handle fractions on ice. Cleavage of protein tags can be performed on or off the column using the appropriate protease to target the relevant protease-specific cleavage site.
4. In vitro ubiquitin chain cleavage assay
NOTE: Select ubiquitin chain length and linkage types based on DUB specificity described in previous reports31 or determined empirically. If necessary, this protocol could be used to test the activity of the wild-type DUB of interest on a panel of commercially available ubiquitin chains of defined length and linkage type. A di-ubiquitin chain amount of 375-750 ng and a DUB concentration of 1-2 µM can be used as starting points for the assay27.
Figure 1: Schematic of the study design. (A) Transformation of competent E. coli cells with recombinant protein expression plasmid. (B) Overnight bacterial expression of recombinant deubiquitylase protein. (C) Protein purification of recombinant deubiquitylase using a gravity-flow affinity column. (D) In vitro ubiquitin chain cleavage assay to evaluate deubiquitylating activity. Please click here to view a larger version of this figure.
To determine the impact of XLID105-associated variants on USP27X catalytic activity, GST-tagged wild-type USP27X and the XLID105-associated variant F313V, Y381H, and S404N USP27X proteins were purified from bacteria. These variants are located within the USP catalytic domain of USP27X (Figure 2A). Because USP27X was previously reported to cleave K63 ubiquitin chains31, wild-type USP27X and the XLID105-associated variant F313V, Y381H, and S404N USP27X proteins were incubated with K63-linked di-ubiquitin chains for 1 h. These samples were separated via SDS-PAGE32, and ubiquitin and USP27X proteins were analyzed via immunoblotting. Wild-type USP27X induces di-ubiquitin cleavage, generating mono-ubiquitin (Figure 2B and Supplementary Figure 1). XLID105-associated F313V, Y381H, and S404N USP27X variant proteins did not cleave these chains. Because F313V, Y381H, and S404N variants disrupt USP27X catalytic activity, USP27X functional disruption appears to be the major mechanism underlying XLID1057. Additional quantification and complementary experiments were previously reported7.
Figure 2: Impact of XLID105 variants on USP27X deubiquitylating activity. (A) Diagram of the human USP27X protein structure, showing residue numbers and the location of the XLID105 variants evaluated in the USP domain (purple). (B) GST-tagged wild-type USP27X and XLID105 variants (F313V, Y381H, and S404N) were incubated with K63 di-ubiquitin chains for the indicated times. Immunoblot analysis was performed using anti-GST (USP27X) and ubiquitin antibodies. Please click here to view a larger version of this figure.
Supplementary Figure 1: Uncropped blots of Figure 2B. Please click here to download this File.
This article presents a protocol for the expression and purification of recombinant USP27X DUBs and an in vitro ubiquitin chain cleavage assay to compare the deubiquitylating activity of wild-type USP27X and NDD-associated variant proteins. This assay determined that XLID105-associated variants disrupt USP27X catalytic activity7. This mechanistic insight helped us define XLID105 as a USP27X functional disruption disorder.
This protocol can be adapted to other DUBs that are associated with genetic diseases with poorly understood molecular mechanisms. The optimization of the expression and purification protocol for a specific DUB of interest is crucial. If no specific protocols have been described for a given DUB of interest, the method described here can act as a starting point. When optimizing a protein expression and purification protocol, critical steps include selecting the appropriate parameters for (1) the expression system (e.g., bacteria strains, insect cells, or mammalian cells), (2) the expression vectors, (3) the tag and affinity resin to be used, (4) the growing conditions, (5) the amounts of culture, and (6) the need for further purification (e.g., via size exclusion or ion exchange chromatography). Specific recommendations for these and other aspects of the method have been discussed33.
The in vitro ubiquitin chain cleavage assay is a simple way to measure the deubiquitylating activity of wild-type or mutant DUBs. A time-dependent analysis of ubiquitin cleavage can provide insights into the effects of genetic variation on DUB enzymatic kinetics by allowing the determination of parameters such as the Km and Vmax. This would enable one to distinguish between defects in the DUB active site that impair catalysis (reduced Vmax) and those that impair substrate recognition (increased Km). The versatility of this assay stems from the variety of ubiquitin chains that can be used to provide distinct mechanistic information on a DUB of interest. Ubiquitin chains of different lengths and linkage topologies are commercially available, rendering this assay accessible to non-experts. Specific DUBs have unique properties for enzymatic kinetics, linkage recognition, and cleavage. Critical steps for this assay include (1) defining a working concentration of the DUB, (2) determining the optimal reaction time, (3) choosing the ubiquitin chain linkage type and length, and (4) selecting a detection method.
Ubiquitin chain cleavage assays measure the impact of NDD variants on DUB activity7,11, helping to identify variants that disrupt DUB activity and drive atypical development. This assay can be used in a range of situations where genetic variation drives pathology, including cancer and neurodegeneration. As a substrate-independent assay, prior identification of a specific ubiquitylated protein substrate is not required. However, the assay is limited to measuring changes in ubiquitin chain cleavage activity and cannot assess variants' effects on DUB functions such as protein-protein interactions, subcellular localization, and posttranslational modifications. Identification of the broad signaling pathways where a DUB of interest operates is required to develop specific assays to address how these variants drive discrete NDDs.
The authors have nothing to disclose.
This work was funded by Sanford Research startup funds to FB and the NIH grant R01CA233700 to MJS. The artwork was done by Felipe G. Serrano (www.illustrative-science.com). We thank Dr. Greg Findlay (University of Dundee) for the GST-USP27X plasmid.
Amersham Protran 0.45 NC 200 mm × 200 mm 25/PK | Cytiva | 10600041 | |
Ammonium sulfate | Fisher Scientific | AC205872500 | |
Ampicillin | Fisher Scientific | BP1760 25 | |
Anti- Ubiquitin (Mouse monoclonal) | Biolegend | Cat# 646302, RRID:AB_1659269 | (WB: 1:1000) |
Anti-GST (Sheep polyclonal) | MRC-PPU Reagents and Services | Cat# S902A Third bleed | (WB: 1:1000) https://mrcppureagents.dundee.ac.uk/ |
Baffled Culture Flasks 2 L | Fisher Scientific | 10-042-5N | |
Bradford Reagent | Millipore Sigma | B6916-500ML | |
Chloramphenicol | Gold Biotechnology | C-105-25 | |
Complete, Protease Inhibitor tablets | Millipore Sigma | 5056489001 | |
Econo-Column 1.5 × 5 cm | Bio-Rad | 7371507 | |
Eppendorf ThermoMixer F1.5 | Eppendorf | 5384000020 | |
Excel | Microsoft | https://www.microsoft.com/en-us/microsoft-365/excel | |
Glycerol | Genesee Scientific | 18-205 | |
Illustrator | Adobe | https://www.adobe.com/products/illustrator.html | |
Image Studio | LI-COR Biosciences | https://www.licor.com/bio/image-studio/ | |
Inkscape | Inkscape | https://inkscape.org/ | |
Invitrogen 4-12% NuPAGE 1mm 12 well gel | Thermo Fisher Scientific | NP0322BOX | |
IPTG (Isopropyl-b-D-Thiogalactopyranoside) | Genesee Scientific | 20-109 | |
IRDye 800CW Donkey anti-Goat IgG Secondary Antibody | LI-COR Biosciences | Cat# 926-32214 | (WB: 1:10000) |
IRDye 800CW Donkey anti-Mouse IgG Secondary Antibody | LI-COR Biosciences | Cat# 926-32212 | (WB: 1:10000) |
Isotemp Digital Dry Bath | Fisher Scientific | 88860022 | |
K63 Di-Ubiquitin | South Bay Bio LLC | SBB-UP0072 | |
LB Agar | Genesee Scientific | 11-119 | |
LB Broth | Genesee Scientific | 11-118 | |
Lysozyme | Gold Biotechnology | L-040-100 | |
MaxQ 4000 Benchtop Orbital Shaker | Thermo Fisher Scientific | SHKE4000-7 | |
MES-SDS Running Buffer | Boston Bioproducts Inc | BP-177 | |
Mini Tube Rotator | Fisher Scientific | 88-861-051 | |
NuPage LDS Sample buffer 4x | Thermo Fisher Scientific | NP0007 | |
Odyssey Fc Imager | LI-COR Biosciences | 43214 | |
PageRuler Plus Ladder | Thermo Fisher Scientific | 26620 | |
pGEX6P1 human USP27X | MRC-PPU Reagents and Services | DU21193 | https://mrcppureagents.dundee.ac.uk/ |
pGEX6P1 human USP27X F313V | Addgene | 225715 | Koch et at 2024 (PMID: 38182161) |
pGEX6P1 human USP27X S404N | Addgene | 225717 | Koch et at 2024 (PMID: 38182161) |
pGEX6P1 human USP27X Y381H | Addgene | 225716 | Koch et at 2024 (PMID: 38182161) |
Pierce Glutathione Agarose | Thermo Fisher Scientific | 16100 | |
PMSF (Phenylmethylsulfonyl fluoride) | Gold Biotechnology | P-470-10 | |
Polysorbate 20 (Tween 20) | Fisher Scientific | AC233360010 | |
Rosetta 2 Competent Cells | Millipore Sigma | 71402-M | |
SimplyBlue SafeStain | Thermo Fisher Scientific | LC6060 | |
SmartSpec 3000 | Bio-Rad | 170-2501 | |
SOC medium | Thermo Fisher Scientific | 15544034 | |
Sodium chloride | Genesee Scientific | 18-216 | |
Sonifier 250 | Branson | 100-132-135 | |
Sorvall RC 6 Plus Centrifuge | Thermo Fisher Scientific | 46910 | |
TCEP (Tris-(carboxyethyl) phosphine hydrochloride) | Gold Biotechnology | TCEP10 | |
Terrific Broth Powder | Genesee Scientific | 18-225 | |
Tris Base | Genesee Scientific | 18-146 | |
XCell SureLock Mini-Cell and XCell II Blot Module | Thermo Fisher Scientific | EI0002 |
.